Patent intelligence · US
US 6887862
Method for improving treatment selectivity and efficacy using intravascular photodynamic therapy
Method for improving treatment selectivity and efficacy using intravascular photodynamic therapy
Patent details — US 6887862
- Jurisdiction
- US
- Status
- expired
- Grant date
- May 3, 2005
- Expiration
- Apr 28, 2025
- Applicant
- Miravant Systems, Inc.
- Claims
- 59
- CPC classes
- A61K, A61K41/0071, A61K41/0076
Quick answer
US 6887862 (Method for improving treatment selectivity and efficacy using intravascular photodynamic therapy) is held by Miravant Systems, Inc.. Status: expired. Granted May 3, 2005. Expires Apr 28, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Miravant Systems, Inc.
- Grant date
- Expiration
- Claims
- 59
- CPC classes
- A61K, A61K41/0071, A61K41/0076
More from Miravant Systems, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 6887862?
US 6887862 (Method for improving treatment selectivity and efficacy using intravascular photodynamic therapy) is held by Miravant Systems, Inc.. Status: expired. Granted May 3, 2005. Expires Apr 28, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6887862?
Miravant Systems, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 6887862 expire?
Our index shows an expiration date of Apr 28, 2025 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.